Keith Wayne Ward - 29 Feb 2024 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Reporting relationship: Director
Issuer ticker: SKYE
Reported as of: 29 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2024, 06:23:17 UTC
Prior SEC filing: 06 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Kaitlyn Arsenault, as Attorney-in-Fact

Key filing fact

Keith Wayne Ward filed Form 4 for Skye Bioscience, Inc. (SKYE) on 04 Mar 2024.

Key facts

This page summarizes Keith Wayne Ward's Form 4 filing for Skye Bioscience, Inc. (SKYE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2024, 06:23.

Change

Previous filing in this sequence was filed on 06 Nov 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SKYE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +35,000
Change %
Price: $0.000000
Shares after: 35,000
Date: 29 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $14.56
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.